SLC5A2 and diabetes mellitus: Related to this, in randomized controlled trials (RCTs) of SGLT2 inhibitors with cardiovascular outcomes, the incidence of urinary tract infections was higher in patients with diabetes; however, a meta-analysis of four RCTs found that there was no difference in the odds of urinary tract infections between diabetic patients and those without diabetes [40,43].